NCCN COVID-19 vaccination recommendations for patients with hematologic malignancies

Patients with cancer are at high risk of COVID-19-associated complications and, accordingly, the preliminary...

Positive topline results from a phase II trial of antroquinonol for patients with AML

On November 26, 2020, a press release on topline results from a phase II trial (NCT03823352) of antroquinonol in...

Predictive factors of mortality in patients with hematological malignancies diagnosed with COVID-19

During this COVID-19 pandemic, patients with hematological malignancies—who are immunocompromised...

An update on the NCRI AML20 trial

During the 2nd National Cancer Research Institute (NCRI) AML Academy meeting, which took place on October 8–9, 2020, we spoke to Executive Steering Committee Member...

FDA grants orphan drug designation to eprenetapopt for TP53-mutated AML

Very recently, eprenetapopt (APR-246), a small molecule that reactivates mutant and inactivated p53 protein, was granted orphan...

Is a TP53 mutation always a poor prognostic marker for transplantation in AML?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to...

Eprenetapopt with azacitidine for TP53-mutant MDS/AML: Results from two ongoing clinical trials

Patients with TP53-mutant myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) experience...

Introduction to a series of podcasts on the use of venetoclax combinations in mutation subtypes of AML

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub...

FDA approves extended indication of daunorubicin plus cytarabine to include pediatric patients with AML

On March 30, 2021, the U.S. Food and Drug Administration (FDA) approved an extended indication...

Augmented reduced-intensity allo-HSCT in patients with high-risk AML or MDS: Results of the FIGARO trial

Previously, older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS)...

How cytogenetic risk impacts the outcome of allogeneic stem cell transplantation

Cytogenetic profile is a predictor of outcome in patients with acute myeloid leukemia (AML). It also helps with the...

How does the mutation profile differ between patients with MDS–AML and de novo AML?

During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to James Yu, AdventHealth Orlando, Orlando, US....